|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
22nd Century Group, Inc.
| | | Phone: | (716) 270-1523 | Fax: | (716) 877-3064 | Year Established: | 1998 | Ticker: | XXII | Exchange: | OTCBB | Main Contact: | Henry Sicignano III, President & CEO | | Other Contacts: | Michael Zercher, VP, Business Development Thomas L. James, Esq., VP & General Counsel John T. Brodfuehrer, CFO Michael Moynihan, Ph.D., VP, R&D James E. Swauger, Ph.D., Senior VP, Science & Regulatory Affairs
| | Company Description | 22nd Century Limited, a wholly-owned subsidiary of 22nd Century Group, is a plant biotechnology company whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and breeding. 22nd Century owns or is the exclusive worldwide licensee of 98 issued patents in 79 countries where at least 75% of the world’s smokers reside. The company is committed to developing and commercializing the world’s most effective and acceptable smoking cessation aid and for those smokers who refuse to quit smoking, consumer-acceptable modified risk tobacco products that reduce exposure to smoke toxins, as compared to conventional cigarettes. | |
|
|
|
|
|